Search

ProQR Announces Results for the Second Quarter of 2017

Press release

Key updates

August 16, 2017
ProQR’s Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA

Press release

Key Updates

July 05, 2017
ProQR R&D day Highlights Progress on Pipeline and Introduces Axiomer®, a novel proprietary RNA Technology

Press release

Key program features and updates:

June 15, 2017
ProQR to Participate in a Cystic Fibrosis Panel Discussion during the JMP Securities Life Science Conference

Press release

LEIDEN, The Netherlands, June 13, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

June 13, 2017
ProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial

Press release

Key Updates

June 08, 2017
ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10

Press release

Key Updates

May 31, 2017
ProQR Announces Results for the First Quarter of 2017

Press release

Key updates

May 17, 2017
ProQR remembers co-founder Henri Termeer after his unexpected passing

Press release

LEIDEN, the Netherlands, May 15, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), remembers co-founder and supervisory board member Henri A. Termeer, who unexpectedly passed away Friday May 12, 2017 at age 71 at his house in Marblehead, MA.

May 15, 2017
ProQR Announces R&D Day in New York on June 15

Press release

Key updates:

May 09, 2017
ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome

Press release

Key updates

May 01, 2017